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Abstract- One of the main members of the large aggregating proteoglycans (PGs) family is versican which 
is able to bind to hyaluronate. Versican is a chondroitin sulfate proteoglycan and is a key ingredient of the 
extracellular matrix.  Due to its widespread expression in the body, versican is involved in cell adhesion, 
proliferation and migration. Induced expression of versican is often observed in tissues such as breast, brain, 
ovary, gastrointestinal tract, prostate, and melanoma. In addition, versican has important role in development. 
For example, versican conducts the embryonic cell migration which is essential in the formation of the heart 
and outlining the path for neural crest cell migration. Several studies in the past decade up to now have shown 
that versican produced by mononuclear cells has an important role in wound healing and blood vessel 
formation and suggested that it promotes tumorigenesis and angiogenesis. In this mini-review, we summarise 
and discuss the role of versican in healthy and pathological tissues and suggest the possible function of 
transcription factors and signalling pathway in regulation of versican. 
© 2013 Tehran University of Medical Sciences. All rights reserved.  
Acta Medica Iranica, 2013; 51(11): 740-750.  
 




The extracellular matrix (ECM) which provides 
structural support for organs and tissues (1) is also 
forming the basement membranes for the cell layers (2) 
and cell migration (3). ECM is composed of collagens 
and elastic fibres which are embedded in a viscoelastic 
gel that comprises proteoglycans (e.g. versican and 
hyaluronan), glycoproteins and water (4,5). ECM forms 
a complex, three-dimensional network among the cells 
of different tissues in an organ-specific manner (6) and 
plays vital roles in the differentiation, proliferation and 
survival of cells (7-9).  
Proteoglycans are the main components of ECM, and 
are characterised by a protein portion (core protein) and 
one or more unbranched, long and negatively charged 
polysaccharide chains called glycosaminoglycans 
(GAG) which are covalently attached to the core protein 
(10,11). Depending upon the nature of the GAG chains, 
proteoglycans can be categorised as heparan sulphate 
proteoglycans, chondroitin sulphate proteoglycans 
(CSPGs) and dermatan sulphate proteoglycans, or 
keratan sulphate proteoglycans (12,13). Of these, the 
CSPGs such as versican are the most abundant type of 
proteoglycan in the ECM of mammalian tissues (14,15). 
 
Versican structure  
Versican is a large chondroitin sulphate proteoglycan 
which is a major component of the ECM (16). Versican 
is transcribed from a single gene which is localized on 
chromosome 5q 12–14 in the human genome and 
extends over 90 kb (17) which is divided into 15 exons 
which range in size from 76 to 5262 bp (16). The 
alternative mRNA-splicing of these exons gives rise to 
four different versican isoforms which are distinguished 
by different core-middle regions (18). Versican is 
comprised of three domains. The amino terminal G1 
domain interacts with a GAG called hyaluronan present 
in the extracellular matrix (14). The carboxyl terminal 
domain of versican is called the G3 domain and it 
contains a C-type lectin binding domain, two epidermal 
growth factor repeats and a complement regulatory 
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region. The versican core protein contains the GAG 
attachment region and the chondroitin sulphate chains 




The central area of versican is encoded by two exons 
that specify chondroitin sulphate attachment regions 
(14). RNA splicing of these two exons generates four 
isoforms of versican named V0, V1, V2 and V3 core 
protein molecular weight of about 370 kDa, 263 kDa, 
180 kDa, and 74 kDa, respectively (18). V0, the largest 
versican isoform, is encoded by exons 7 and 8 and 
contains the GAG-α and β domains. The V1 isoform 
contains GAG-β attachment domain which is encoded 
by exon 8 (lacking exon 7) whereas the V2 isoform 
contains a GAG-α domain which is encoded by exon 7 
(lacking exon 8) (22). V3 does not include either exon 7 
or 8 and consequently has no GAG attachment sites 
(Figure 2) (19,22).  
 
 
Figure 1. Schematic model of versican structure. Versican contains globular domains at the amino terminus (G1) and carboxyl 
terminus (G3). The G1 domain is composed of an immunoglobulin-like motif, followed by two proteoglycan tandem repeats which 
bind hyaluronan (HABR; hyaluronan binding region). The G3 domain contains two epidermal growth factor-like repeats, a 
carbohydrate recognition domain (a lectin-binding domain) and complement binding protein (ELC). The core-middle region of 
versican contains GAG attachment regions that are encoded by exons 7 and 8 which give rise to four different versican isoforms.  
GAG chondroitin sulphate chains extend from the core protein (21).  
 
 
Figure 2. Cartoon of versican isoforms generated by alternative splicing of the mRNA transcript. Different colours show specific 
domains in the gene. G1 and G3 are shown at the amino and carboxyl termini respectively. Purple = hyaluronan binding region 
(HABR); yellow = α GAG exon; red = β GAG exon and green = epidermal growth factor repeats (E), a lectin binding domain (L) 
and a complement regulatory region (C). The glycosaminoglycan chondroitin sulphate chains are shown as (/)    
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Figure 3. Sequence analysis of versican gene promoter and exon 1. Naso et al., revealed a typical TATA box located approximately 
16 bp upstream of the transcription start site and binding sites for a number of transcription regulatory factors including CREB at 
position -36 bp, SP-1 at position -370 bp, XRE at position -509 bp and AP-2 at positions -426 bp, -355 bp, -218 bp and -190bp 
respectively (16). Rahmani et al., showed two binding sites for TCF/LEF at positions -546 bp and -492 bp respectively (29). Also 
further investigation by Domenzain et al., revealed one binding site for SP-1 at position -166 bp and one binding site for AP-1 at 
position -36 bp. Positions of all transcription factors are relative to the transcription start site (30). The sequence of exon 1 is shaded. 
CREB; cAMP response element-binding, AP-1& 2; (activator protein 1&2), XRE; xenobiotic responsive element, TCF/LEF; T-cell 
factor/lymphoid enhancer factor. 
 
 
An interesting study on human adult tissues showed 
that all four versican isoforms are transcribed in more 
than 50% of tissues, although, intriguingly, only the V1 
isoform is expressed in liver and spleen (23). Another 
study suggested that V1 versican enhances cell 
proliferation and protects mouse fibroblast cell lines 
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from apoptosis whereas the V2 isoform exhibits 
opposite activities by inhibiting cell proliferation (24).  
In addition, it has been reported that V0 and V1 are 
the predominantly expressed isoforms in tumours 
suggesting that these isoforms are mainly involved in 
tumour development (25,26). In contrast, over-
expression of V3 (the smallest versican isoform which 
consists of only the G1 and G3 domains) markedly 
reduced cell growth in melanoma cancer cells, 
suggesting a role for V3 versican as an inhibitor of 
tumour growth (27,28). 
 
Versican promoter 
The transcription start site for the versican gene was first 
identified by Naso et al., in 1994 (16). This study 
reported that the versican promoter contains a typical 
TATA box located approximately 16 base pairs 
upstream of the transcription start site (Figure 3). 
Transient transfection of a reporter construct driven by 
an 876-bp (-632/+240) fragment of the versican 
promoter showed significant expression in HeLa cells 
and IMR-90 embryonic lung fibroblasts. Furthermore, 
deletion constructs of the 876-bp confirmed that the 
human versican 5’-flanking sequence contains promoter, 
enhancer and repressor elements which are able to drive 
the expression of the versican reporter gene in different 
cells (14). In addition, sequence analysis has revealed 
potential binding sites for several transcription factors in 
the 876 bp versican promoter region including CREB 
(14), T-cell factor/ lymphoid enhancer-binding factor  
(TCF/LEF) (29), AP-1 and SP1 (30) (Figure 3). 
 
Versican function 
Versican is a main component of the ECM where its 
hygroscopic properties create a loose and hydrated 
matrix which is necessary to support key events in 
development (31,32). Versican is found in a variety of 
tissues including the brain (33) and skin (34). Increased 
expression of versican is also observed in sites of tissue 
injury (35) and in cancers including breast (36), ovarian 
(37), gastrointestinal tract (38), prostate (39), brain (40), 
cervical (41) and melanoma (42). Several reports have 
also highlighted the role of versican in wound healing 
(23), angiogenesis, tumour growth (43) and in vascular 
diseases, especially atherosclerosis (44,45). It has been 
demonstrated that versican binds low-density lipoprotein 
(LDL) particles and it is believed that accumulation of 
versican in blood vessels promotes extracellular 
lipoprotein retention, suggesting roles in lipid 
accumulation, inflammation and thrombosis (46,47). 
Due to versican’s structural composition and its 
widespread expression in the body it is able to regulate 
cell adhesion and survival, cell proliferation, cell 
migration and ECM assembly (48) that the key studies 
in these areas are reviewed below. 
  
Cell adhesion 
Early studies reported that most chondroitin sulphate 
proteoglycans may be considered as anti-adhesion 
molecules for the regulation of cell adhesion to the 
substratum, which is essential for various cell and tissue 
functions (49,50). Different studies presented evidence 
suggesting that this inhibitory activity could be to due to 
the G1 domain of versican (49,51). They showed that 
selective exclusion of versican from podosomes of 
cultured human osteosarcoma cells suppresses the 
malignant cell-adhesive phenotype, suggesting that 
versican can act as an anti-adhesive molecule (52). 
However there is evidence that the carboxy-terminal 
domain of versican interacts with the β1 integrin of brain 
tumour cells leading to the activation of focal adhesion 
kinase (FAK), promoting cell adhesion and protecting 
the cell from apoptosis (53,54).  
Interaction of versican with selectins and 
chemokines has been studied. It has been shown that 
versican binds to selectins, adhesion molecules on the 
surface of activated endothelial cells, through its 
chondroitin sulphate chains (55). In addition, versican 
has been shown to bind secondary lymphoid tissue 
chemokine (SLC) through chondroitin sulphate chains 
and this binding tends to down-regulate chemokine 
function for recruitment of lymphocytes (56). Taken 
together the data suggest that versican, which is induced 
in inflammatory conditions such as arthritis (57), asthma 
and lung disease (58,59), may regulate inflammation by 




Abundant expression of versican in fast growing 
tissues and cells suggested a key role for versican in cell 
proliferation (60,61). For example high expression of 
versican is detected in the loose connective tissue of 
various organs including the central and peripheral 
nervous system (60), blood vessels (62), dermis and in 
the proliferative zone of the epidermis (34).  
Versican is also involved in the proliferation of 
smooth muscle cells (SMC) (63,64). Several  
studies have reported proteins such as platelet- 
derived growth factor (PDGF) and transforming growth 
factor-β 1 (TFG-β1) increase versican synthesis in 
arterial smooth muscle cells (ASMCs) (63,65). It  
Versican; structure, function and regulation 
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was demonstrated that increases in versican and  
the associated protein hyaluronan in response to  
PDGF and TFG-β1 cause increases in the pericellular 
matrix of the cells and expansion of the ECM that is 
required for the proliferation and migration of these  
cells (66). In addition it was shown that proliferation  
of ASMCs treated with PDGF is blocked by  
inhibition of the formation of versican- 
hyaluronan complex which serves as an important 
mechanism for controlling cell shape and cell division 
(67).  
Other studies have suggested a role for versican in 
cell proliferation through its two epidermal growth 
factor sequences in the G3 domain of the molecule (68, 
69). These studies showed that expression of the G3 
domain of versican promotes proliferation in NIH3T3 
fibroblasts cells whereas this effect can be inhibited by 
removing EGF motifs in the versican G3 domain (68). 
These results suggested that the EGF-like motifs in the 
versican G3 domain may promote cell proliferation 
through direct or indirect interaction with the EGF 
receptor (EGFR) (70). 
 
Cell migration 
Controversial studies have demonstrated that 
versican is widely expressed at both mRNA and protein 
level in neural crest pathways and influences neural cell 
migration (71) whereas a number of other studies have 
shown that versican prevents migration of these cells 
(35,72). These contradictory findings are believed to be 
due to different versican isoforms which differ in the 
core-middle region (73). Some studies have investigated 
the role of versican in the nervous system and axonal 
outgrowth (74-76). These studies showed that 
chondroitin sulphate (CS) chains of versican isotype  
V2 are involved in inhibiting axonal outgrowth  
and migration of the mature nervous system. The  
role of versican in axonal migration was investigated  
by Asher et al., in 2002 (77) who showed up-regulation 
of versican following central nervous system (CNS) 
injury and suggested these changes in versican 
regulation are associated with the failure of nerves to 
regenerate. 
As mentioned earlier, the G3 domain of versican can 
interact with integrin β1 which is able to form clusters 
with EGF receptors (78). Growing evidence indicates 
that interaction of integrins with EGF receptors induces 
down-stream signal to extracellular regulated kinase 
(ERK) which is crucial in regulating a range of cell 
activities, such as migration (79-81). Also, the role of 
versican in the migration of embryonic cells in the 
development of the heart has been studied (82, 83). It 
has been reported that versican mRNA and protein is 
strongly expressed during the development of mouse 
heart suggesting a key role for versican in cardiac 
development (82). 
Furthermore other studies have reported that  
the G3 domain of versican directly interacts with 
fibronectin, another extracellular matrix glycoprotein 
(84) and showed that formation of a complex of  
versican G3 domain and fibronectin with VEGF can 
enhance endothelial cell migration which this process 
was reversed by removal of the complex (43).  
This study and other investigation by Wijelath  
et al., in 2002 (85) indicated that expression of  
versican G3 enhanced brain tumour growth, suggesting 
the role of versican G3 fragment on promoting 
angiogenesis and tumour growth that it suggests 
targeting versican G3 fragments may help to develop a 
new approach for anticancer and anti-angiogenic 
therapies. 
 
Extracellular matrix assembly 
Versican interacts with different ECM molecules and 
has been reported to have an important role during ECM 
assembly (21). Possibly the best known is a specific 
interaction between the G1 domain of versican and 
hyaluronan (86). Hyaluronan is a large polysaccharide in 
the ECM and is able to create a lattice structure which 
may regulate cell adhesion and migration (87). Versican 
binds hyaluronan and this binding requires the double 




Signal transduction pathways 
The signalling pathways which modulate versican 
synthesis are not fully understood although studies on 
the intracellular pathways have reported that PDGF-
stimulated versican expression in arterial smooth muscle 
cells (SMC) is regulated by endogenous tyrosine kinase 
activity of the PDGF receptor which up-regulates 
versican synthesis at both mRNA and protein levels in 
vascular smooth muscle cells (63,90). In addition, 
another study has suggested the role of protein kinase C 
(PKC) and ERK in the PDGF stimulated versican gene 
expression in non-human ASMC (91).  
An interesting study by Rahmani et al., in 2005 (29) 
demonstrated the role of the PI3-K/ PKB (Protein kinase 
B) pathway in versican expression in SMC. They 
suggested that phosphorylation and inactivation of 
glycogen synthase kinase-3β (GSK-3β), a downstream 
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effector of PI3K/PKB (92), leads to activation and 
nuclear accumulation of β-catenin which binds to the 
TCF/LEF transcription factors in the versican promoter 
and then increases versican transcription in SMC (Figure 
4) (29). Further investigation by this group using a 
specific inhibitor of the PI3-Kinase pathway, 
LY294002, showed inhibited activation of downstream 
PKB and resulted in significant inhibition of versican 
promoter reporter activity and versican mRNA 
expression in SMC. A similar mechanism has been 
observed for other genes such as MMP-7 (93) and 
VEGF (94), which have also been shown to be targeted 
by PI3-K/PKB and up-regulated by formation of a β-
catenin TCF/LEF complex. 
 
Transcription factors  
Analysis of the versican promoter by Rahmani et al., 
in 2005 (29) revealed two putative binding sites for 
TCF/LEF transcriptions factors at positions -546 and -
492 bp relative to the transcription start site (Figure 3). 
They showed that site-directed mutagenesis of the TCF 
sites in the versican promoter markedly diminished 
reporter luciferase activity in SMC. Furthermore, 
electrophoretic mobility shift assay (EMSA) and 
supershift assays revealed that the β-catenin/ TCF 
transcription factor complex is essential for versican 
expression in SMC (29). 
A recent study by Domenzain et al., identified 
several other transcriptional regulatory elements 
including AP1, SP1 and AP2 on a 620 bp (-618/+2 
relative to the transcriptional start site) in a proximal 
versican promoter reporter construct (30). This study 
demonstrated that mutagenesis of the AP-1 site at 
position -36 bp completely abolished versican promoter 
activity in human melanoma cell lines. Also further 
investigation by EMSA confirmed the importance of the 
AP-1 binding site for versican promoter transcription in 
these cell lines. In addition, versican promoter activity in 
a TCF/LEF mutated construct was reduced by half, 
suggesting that versican expression is also up-regulated 
via the β-catenin/TCF pathway in human melanoma cell 




Figure 4. Schematic model of versican promoter regulation via PI3/PKB signalling and β-catenin TCF transcription factor complex 
suggested by Rahmani et al. (29). Activation of PI3K signalling by growth factors leads to phosphorylation and inactivation of GSK-
3β which results in β-catenin cytoplasmic accumulation and subsequent translocation to the nucleus. Nuclear accumulation of β-
catenin leads to complex formation with TCF/LEF transcription factors and transactivation of TCF/LEF target genes. Specific 
inhibitors of the PI3K signalling pathway such as LY294002 and wortmannin lead to activation of GSK-3β and subsequently to β-
catenin degradation.  
 
 
Versican; structure, function and regulation 
746    Acta Medica Iranica, Vol. 51, No. 11 (2013)   
 
Yoon et al., investigated the role of the transcription 
factor p53 in versican gene expression in a broad range 
of human carcinoma cell lines (95). P53 is a 
transcription factor involved in important cellular 
processes such as cell cycle checkpoint regulation, DNA 
damage and apoptosis (96,97). Oligonucleotide-array 
gene expression analysis of human carcinoma cell lines 
by Yoon et al., demonstrated high expression of the 
versican gene in wild type p53 (p53 +/+) cells but lower 
expression in p53 -/- cells, suggesting that versican is a 
direct target of p53. Further investigation using wild 
type p53 over-expression in p53-null cells transfected 
with versican promoter reporter constructs showed 200-
fold increases in luciferase activity in comparison with 
the control plasmid. EMSA and super-shift assays 
confirmed the interaction of p53 protein and the versican 
p53 binding site (95). In conclusion, in the present 
review, I provided evidence about versican structure, 
regulation and its role in normal tissue and tumour 
growth. In addition, this review discussed the function 
of versican as a key factor in inflammation through 
interactions with adhesion molecules on the surfaces of 
inflammatory leukocytes and interactions with 
chemokines that are involved in recruiting inflammatory 
cells. A better understanding of how versican is 
regulated will hopefully be helpful for the development 
of future therapies for a range of different disease such 
as vascular disorders, including atherosclerosis, where 
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